Innoviva, a healthcare focused asset management company, completed a $25m investment in Armata Pharmaceuticals, a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections. "The completion of our $25m financing with Innoviva provides our company with significant resources that will allow us to efficiently advance our pipeline of phage-based therapeutics to treat multi-drug resistant bacterial infections," Todd R. Patrick, Armata CEO.